September 24, 2013

U.S. FDA Approves Merial’s NexGardTM (afoxolaner) Chewables for Treatment and Prevention of Fleas and Ticks in Dogs

New Oral Treatment from Sanofi’s Animal Health Division Adds to Company’s Strong Parasiticide Portfolio

 

U.S. FDA Approves Merial’s NexGardTM (afoxolaner) Chewables for Treatment and Prevention of Fleas and Ticks in Dogs
New Oral Treatment from Sanofi’s Animal Health Division Adds to Company’s Strong Parasiticide Portfolio

Paris, France – September 24, 2013 – Sanofi (EURONEXT: SAN and NYSE: SNY) and its animal health division Merial today announced that the U.S. Food and Drug Administration (FDA) has approved NexGardTM (afoxolaner) Chewables for the treatment and prevention of flea infestations, and treatment and control of the American Dog tick in adult dogs and puppies, for one month.